Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma

World Journal of Surgical Oncology

Volumn 4, Issue , 2006, Pages

  Lin, Ho Sheng ^a,b   Berry, Gerald J ^c   Sun, Zijie ^d   Fee Jr , Willard E ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLIN D1; PROTEIN ANTIBODY; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EAR NOSE THROAT SURGERY; FEMALE; GENE LOSS; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RESEARCH; NASOPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RECURRENT CANCER; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 33749339342     PISSN: 14777819     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-4-62     Document Type: Article

References (19)

1. Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH: Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope 1992, 102:965-972.
2. Lee AW, Law SC, Ng SH, Chan DK, Poon YF, Foo W, Tung SY, Cheung FK, Ho JH: Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br J Radiol 1992, 65:918-928.
3. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
4. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000, 60:3689-3695.
5. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775-778.
6. Lai S, El-Naggar AK: Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas. Lab Invest 1999, 79:255-260.
7. Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES: Cyclin DI amplification and p16(MTSI/CDK41) deletion correlate with poor prognosis in head and neck tumors. Laryngoscape 2002, 112:472-481.
8. Olshan AF, Weissier MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG: Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 1997, 14:811-818.
9. Hwang CF, Cho CL, Huang CC, Wang JS, Shih YL, Su CY, Chang HW: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002, 13:1246-1251.
10. Baba Y, Tsukuda M, Mochimatsu I, Furukawa S, Kagata H, Satake K, Koshika S, Nakatani Y, Hara M, Kato Y, Nagashima Y: Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect Prev 2001, 25:414-419.
11. Huang GW, Mo WN, Kuang GQ, Nong HT, Wei MY, Sunagawa M, Kosugi T: Expression of p16, nm23-HI, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 2001, 111:1465-1471.
12. Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O'Sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, Warde P, Irish J, Brown D, Gilbert R, Gullane P, Liu FF, Kamel-Reid S: Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003, 9:2177-2184.
13. Fee WE Jr, Moir MS, Choi EC, Goffinet D: Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2- to 17-year follow-up. Arch Otolaryngol Head Neck Surg 2002, 128:280-284.
14. Kuo MY, Lin CY, Hahn LJ, Cheng SJ, Chiang CP: Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999, 28:165-169.
15. Mathew R, Arora S, Khanna R, Shukla NK, Mathur M, Ralhan R: Alterations in cyclin D1 expression in esophageal squamous cell carcinoma in the Indian population. J Cancer Res Clin Oncol 2001, 127:251-257.
16. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995, 55:975-978.
17. Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, Moreno E, Elorriaga J, Alonso I, Baroja A, de la Hoz C: p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003, 113:167-172.
18. Lai JP, Tong CL, Hong C, Xiao JY, Tao ZD, Zhang Z, Tong WM, Betz CS: Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope 2002, 112:402-408.
19. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee JC, Huang DP: Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 1999, 81:1122-1126.